Drugs, Nonprescription -- Labeling -- United States. / https://id.loc.gov/authorities/subjects/sh85039761 https://id.loc.gov/authorities/subjects/sh00006378 https://id.loc.gov/authorities/names/n78095330-781 : United States.
Drugs -- North America -- History -- 20th century. / https://id.loc.gov/authorities/subjects/sh85039719 https://id.loc.gov/authorities/subjects/sh85092455-781 https://id.loc.gov/authorities/subjects/sh2002006165 : Crellin, J. K.
Drugs of abuse -- Identification. / https://id.loc.gov/authorities/subjects/sh94005490 https://id.loc.gov/authorities/subjects/sh2002011456 : United Nations Office on Drugs and Crime.
Drugs of abuse -- Social aspects. / https://id.loc.gov/authorities/subjects/sh94005490 https://id.loc.gov/authorities/subjects/sh00002758 : Boothroyd, Dave,
2006
1
Drugs of abuse -- Standards. / https://id.loc.gov/authorities/subjects/sh94005490 https://id.loc.gov/authorities/subjects/sh00007508 : United Nations Office on Drugs and Crime.
Drugs of limited commercial value -- See Orphan drugs
Here are entered works on drugs which appear to be useful for the treatment of rare disorders, but have difficulty in finding a sponsor for development and marketing because of insufficient anticipated financial return.
Here are entered works on the physiological availability of administered drugs within the body. Works on patients' practical or economic access to therapeutic drugs are entered under Drug accessibility.
Drugs -- Prescribing -- Data processing. / https://id.loc.gov/authorities/subjects/sh85039743 https://id.loc.gov/authorities/subjects/sh99005487 : Institute of Medicine (U.S.).